FDA Approves Amivantamab and Hyaluronidase-lpuj for Subcutaneous Injection By Ogkologos - January 14, 2026 4 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for safety and efficacy is based on the findings from the PALOMA-3 study Source RELATED ARTICLESMORE FROM AUTHOR Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off A Combination of Savolitinib and Osimertinib Prolongs PFS in Patients with EGFR-mutated NSCLC and Acquired MET Amplification After Progression On a First-Line EGFR TKI EMA Recommends Granting a Conditional Marketing Authorisation for Nogapendekin alfa Inbakicept MOST POPULAR One Million Masks Donated! But GreaterGood Will Continue to Help Where... October 5, 2020 Cancer in My Community: Caring for Children With Cancer in Paraguay June 8, 2023 Metastatic Breast Cancer: New ESMO Guideline With Evidence-Based Recommendations [ESMO Press... October 19, 2021 FDA Grants Accelerated Approval to Pembrolizumab for Locally Recurrent Unresectable or... November 16, 2020 Load more HOT NEWS The future of research: meet three of our scientists working on... Should alcohol marketing be dropped from televised sport? Grief Anniversaries EMA Recommends Granting a Conditional Marketing Authorisation for Pralsetinib
